← Leaderboards
Susruta Majumdar
Sloan-Kettering Inst Can Research
$7,293,051
Attributed
$17,268,246
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,268,246 · 13
By mechanism
R01$6,195,752 · 3
UG3$3,966,218 · 3
UH3$1,940,013 · 1
R34$1,573,094 · 1
R33$1,388,194 · 2
R61$1,325,500 · 1
Top collaborators
- Vsevolod Katritch9 shared
- Dalibor Sames9 shared
- Vadim Cherezov5 shared
- Andrew John Shepherd5 shared
- Jay P Mclaughlin4 shared
- Tao Che3 shared
- Ron Dror2 shared
- Robert W Gereau2 shared
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadIn VivoOpioidBrainAnalogReceptorPainOpioid AnalgesicsAnalgesicsIn VitroAbsence Of Pain SensationStructurePharmacologyLigandsPharmaceutical PreparationsDesignPropertyVentilatory DepressionChronic PainAffinityAdverse EffectsSide EffectDrug KineticsAddiction
Grant awards (27)
Development of negative allosteric modulators at the mu opioid receptor$2,664,000
UG3 · FY2025 · DA · contact PI
Development of Angiotensin AT2 inhibitors for neuropathic pain relief$818,360
UG3 · FY2025 · NS
Targeting the allosteric sodium site with novel probes for delta opioid receptor$656,556
R01 · FY2025 · DA · contact PI
Efficacy and signaling modulation by targeting the sodium site at mu opioid receptor$583,724
R01 · FY2025 · DA · contact PI
Development of PAC1 receptor antagonists for the treatment of Headache Disorders$1,325,500
R61 · FY2024 · NS
Targeting the allosteric sodium site with novel probes for delta opioid receptor$664,982
R01 · FY2024 · DA · contact PI
Efficacy and signaling modulation by targeting the sodium site at mu opioid receptor$601,979
R01 · FY2024 · DA · contact PI
Targeting the allosteric sodium site with novel probes for delta opioid receptor$653,137
R01 · FY2023 · DA · contact PI
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$607,440
UH3 · FY2023 · NS
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$647,556
UH3 · FY2022 · NS
Chemistry and Biology of Mitragynine Alkaloids$593,305
R01 · FY2022 · DA
Synthesis of peripherally active CB1 agonists as analgesics$1,033,359
R34 · FY2021 · NS · contact PI
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$685,017
UH3 · FY2021 · NS
Chemistry and Biology of Mitragynine Alkaloids$601,224
R01 · FY2021 · DA
Synthesis of peripherally active CB1 agonists as analgesics$539,735
R34 · FY2021 · NS · contact PI
Pharmacological Probes based on mitragynine pseudoindoxyl$395,106
R33 · FY2021 · DA · contact PI
Chemistry and Biology of Mitragynine Alkaloids$610,212
R01 · FY2020 · DA
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$483,858
UG3 · FY2020 · NS
Pharmacological Probes based on mitragynine pseudoindoxyl$396,993
R33 · FY2020 · DA · contact PI
Chemistry and Biology of Mitragynine Alkaloids$596,155
R01 · FY2019 · DA
Pharmacological Probes based on mitragynine pseudoindoxyl$220,537
R21 · FY2019 · DA · contact PI
Chemistry and Biology of Mitragynine Alkaloids$634,478
R01 · FY2018 · DA
Pharmacological Probes based on mitragynine pseudoindoxyl$216,230
R21 · FY2018 · DA · contact PI
Analgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)$296,333
R33 · FY2015 · DA · contact PI
Analgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)$299,762
R33 · FY2014 · DA · contact PI
Analgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)$214,083
R21 · FY2013 · DA · contact PI
Analgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)$228,625
R21 · FY2012 · DA · contact PI